You are here

  • Home
  • Archive
  • Volume 41, Issue 9
  • Correspondence on 'Methocarbamol versus diazepam in acute low back pain in the emergency department: a randomised double-blind clinical trial' by Sharifi et al

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Correspondence on 'Methocarbamol versus diazepam in acute low back pain in the emergency department: a randomised double-blind clinical trial' by Sharifi et al
  1. Timothy D Kelly1,
  2. Jon B Lee2,3,
  3. Jessica C Oswald4,5
  1. 1 Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
  2. 2 Department of Emergency Medicine, Stanford University School of Medicine, Stanford, California, USA
  3. 3 Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California, USA
  4. 4 Department of Emergency Medicine, UC San Diego Health, San Diego, California, USA
  5. 5 Center for Pain Medicine, Department of Anesthesiology, UC San Diego Health, La Jolla, California, USA
  1. Correspondence to Dr Timothy D Kelly; tykell{at}iu.edu

https://doi.org/10.1136/emermed-2024-214123

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We would like to express our congratulations to Sharifi et al for their recently published randomised, double-blinded clinical trial comparing methocarbamol to diazepam in the treatment of acute back pain in the ED.1 Although skeletal muscle relaxants (SMR) are frequently (and controversially) used in the treatment of low back pain (LBP), there has been a paucity of data to suggest their clinical benefit.2 To our knowledge, this is one of the first investigations that demonstrates the efficacy of both methocarbamol and diazepam for the treatment of LBP in an acute care setting. Given the clinical challenges of treating …

    View Full Text

    Footnotes

    • Handling editor David Metcalfe

    • Contributors All listed authors (TDK, JBL, JCO) meaningfully contributed to the conception, drafting and revision of this correspondence.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests JCO is on the steering committee for Vertex Pharmaceuticals and the transition of care advisory board for Salix Pharmaceuticals.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles